Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203).

被引：2
|
作者：
Chen, Ronald C.
Feuilly, Marion
Meng, Jie
Lister, Johanna
Marteau, Florence
Morris, Michael J.
George, Daniel J.
Choueiri, Toni K.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] IPSEN Pharma SAS, Boulogne, France
[3] Analyt LASER Intl, Lorrach, Germany
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Duke Univ, Durham, NC USA
[6] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4556
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
    David F. McDermott
    Ruchit Shah
    Komal Gupte-Singh
    Javier Sabater
    Linlin Luo
    Marc Botteman
    Sumati Rao
    Meredith M. Regan
    Michael Atkins
    Quality of Life Research, 2019, 28 : 109 - 119
  • [22] Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial.
    George, Daniel J.
    Hessel, Colin
    Halabi, Susan
    Sanford, Ben L.
    Michaelson, M. Dror
    Hahn, Olwen Mary
    Walsh, Meghara K.
    Olencki, Thomas
    Picus, Joel
    Small, Eric Jay
    Dakhil, Shaker R.
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    Morris, Michael J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone vs IPI among treatment-naive patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
    Botteman, M.
    Shah, R.
    Gupte-Singh, K.
    Luo, L.
    Sabater, J.
    Rao, S.
    McDermott, D. F.
    Atkins, M. B.
    Regan, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer (MBC)
    Sherrill, B.
    Allshouse, A.
    Amonkar, M.
    Stein, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
    Choueiri, Toni K.
    Hessel, Colin
    Halabi, Susan
    Sanford, Ben
    Michaelson, M. Dror
    Hahn, Olwen
    Walsh, Meghara
    Olencki, Thomas
    Picus, Joel
    Small, Eric J.
    Dakhil, Shaker
    Feldman, Darren R.
    Mangeshkar, Milan
    Scheffold, Christian
    George, Daniel
    Morris, Michael J.
    EUROPEAN JOURNAL OF CANCER, 2018, 94 : 115 - 125
  • [26] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in a phase II clinical trial.
    Li, Jin
    Xu, Ruihua
    Bai, Yuxian
    Xu, Jianming
    Liu, Tianshu
    Shen, Lin
    Wang, Liwei
    Pan, Hongming
    Han, Rubing
    Chen, Yun
    Peng, Cike
    Fan, Songhua
    Hua, Ye
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [27] ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203).
    Feldman, Darren R.
    Feuilly, Marion
    Meng, Jie
    Lister, Johanna
    Marteau, Florence
    Morris, Michael J.
    George, Daniel J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
    Powles, Thomas
    Cislo, Paul
    Kirker, Melissa
    Chang, Jane
    Gharibian, Norbek
    Thompson, Allison
    Costa, Nuno
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer (mCRC) treated with fruquintinib in the randomized phase III FRESCO trial.
    Bai, Yu-Xian
    Qin, Shukui
    Li, Jin
    Deng, Yanhong
    Yang, Lei
    Xu, Rui-hua
    Zhong, Haijun
    Chen, Zhendong
    Pan, Hongming
    Guo, Weijian
    Shu, Yongqian
    Peng, Cike
    Chen, Yun
    Li, Hongyan
    Wang, Ning
    Guo, Xiaojun
    Wang, Wei
    Fan, Songhua
    Xu, Jian-Ming
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Quizartinib Vs Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)
    Cortes, Jorge E.
    Ganguly, Siddhartha
    Khaled, Samer K.
    Kramer, Alwin
    Levis, Mark J.
    Martinelli, Giovanni
    Perl, Alexander E.
    Russell, Nigel H.
    Botteman, Marc
    Shah, Ruchit
    Luo, Linlin
    Shun, Zhenming
    Ray, Saurabh
    BLOOD, 2019, 134
12345